Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T22:13:17.819Z.
Calculation as of: 2026-10-06T22:13:17.819Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 9e5af3e3eb74887b0741ac42ed15d75d820cdffcd327c1f2ecbbd665592eb47e
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$349.70M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$353.88M
EBITDA Yield
N/A
TTM Avg
3.28%
3Y Avg
4.15%
5Y Avg
7.65%
Market Cap
$355.36M
EBITDA Yield
15.38%
TTM Avg
14.45%
3Y Avg
13.54%
5Y Avg
12.09%
Market Cap
$355.43M
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. (RLMD) | $344.04M | N/A | N/A | N/A | N/A |
| Turn Therapeutics Inc. (TTRX)vs › | $346.73M | N/A | N/A | N/A | N/A |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $349.70M | N/A | N/A | N/A | N/A |
| Ocugen, Inc. (OCGN)vs › | $352.67M | N/A | N/A | N/A | N/A |
| Embecta Corp. (EMBC)vs › | $353.00M | 18.60% | 21.70% | 14.93% | 15.13% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $353.88M | N/A | 3.28% | 4.15% | 7.65% |
| Viemed Healthcare, Inc. (VMD)vs › | $355.36M | 15.38% | 14.45% | 13.54% | 12.09% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.43M | N/A | N/A | N/A | N/A |
| ClearPoint Neuro, Inc. (CLPT)vs › | $330.19M | N/A | N/A | N/A | N/A |
| Cabaletta Bio, Inc. (CABA)vs › | $329.37M | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
